Living donor liver transplantation for patients with advanced hepatocellular carcinoma

Abstract

Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC) and underlying liver disease. Given the organ scarcity, LT for patients with HCC have been restricted to those patients associated with the highest survivals. However, many patients with extended criteria HCC can still benefit from LT, but due to deceased organ shortage, they are not offered that opportunity. Living donor liver transplantation (LDLT) emerged as a successful strategy to overcome organ shortage around the world and as LDLT experience grows, this technique might offer the opportunity to expand the indications of LT to patients with advanced HCC. Therefore, since LDLT is not competing for deceased donor organs, many patients with extended criteria HCC who could still benefit from transplantation may have access to this treatment option. In this review, we will discuss the role of LDLT for patients with advanced-stage HCC and how LDLT allows for safe expansion of HCC transplant criteria.

Keywords

Living donor liver transplantation / hepatocellular carcinoma / liver transplantation / transplant oncology / clinical outcomes

References

[1] Ferlay J,Dikshit R.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Berumen J.Liver transplantation for hepatocellular carcinoma..Abdom Radiol (NY)2018;43:185-92

[3] Proneth A,Schlitt HJ.Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis..Ann Surg Oncol2014;21:3096-107

[4] Mulligan DC.The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond..Hepatology2016;64:1853-5

[5] Sapisochin G,Laurence JM.The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study..Hepatology2016;64:2077-88

[6] Raia S,Mies S.Liver transplantation from live donors..Lancet1989;2:497

[7] Wong TCL,Fung JYY.Long-term survival outcome between living donor and deceased donor liver transplant for hepatocellular carcinoma: intention-to-treat and propensity score matching analyses..Ann Surg Oncol2019;26:1454-62

[8] Cheung TTT,Chan S.Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma..Liver Cancer2018;7:40-54 PMCID:PMC5892367

[9] de Freitas LBR,Santos D,Álvares-da-Silva MR.Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population..World J Hepatol2019;11:678-88 PMCID:PMC6783400

[10] De Souza Martins Fernandes E,Álvares-da-Silva MR.Treatment strategies for locally advanced hepatocellular carcinoma..Transl Gastroenterol Hepatol2019;4:12 PMCID:PMC6414334

[11] Xie DY,Zhou J,Gao Q.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights..Hepatobiliary Surg Nutr2020;9:452-63 PMCID:PMC7423548

[12] Iwatsuki S,Sheahan DG.Hepatic resection versus transplantation for hepatocellular carcinoma..Ann Surg1991;214:221-9 PMCID:PMC1358637

[13] Bigourdan JM,Meyer N.Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation..Liver Transpl2003;9:513-20

[14] Bhangui P,Majno P.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation..Hepatology2011;53:1570-9

[15] Azoulay D,Bhangui P.Living or brain-dead donor liver transplantation for hepatocellular carcinoma..Ann Surg2017;266:1035-44

[16] Goldaracena N,Doyle A.Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation..J Hepatol2019;70:666-73

[17] Xiao GQ,Shen S,Yan LN.Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation..World J Gastroenterol2014;20:10953-9 PMCID:PMC4138476

[18] Fisher RA,Freise CE.Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation..Am J Transplant2007;7:1601-8 PMCID:PMC3176596

[19] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-9

[20] Yao FY,Bass NM.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival..Hepatology2001;33:1394-403

[21] Lee SG,Moon DB.Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center..Liver Transpl2008;14:935-45

[22] Cillo U,Polacco M.Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation..World J Gastroenterol2016;22:232-52 PMCID:PMC4698488

[23] Lee SD,Kim SH.Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria..World J Transplant2016;6:411-22 PMCID:PMC4919746

[24] Uchiyama H,Yoshizumi T.Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years..HPB (Oxford)2017;19:1082-90

[25] Llovet JM,Montaña X.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[26] Wang JC,Xu Y.Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis..J Cell Physiol2019;234:1062-70

[27] Kornberg A,Kornberg J,Thrum K.Serological risk index based on alpha-fetoprotein and C-reactive protein to indicate futile liver transplantation among patients with advanced hepatocellular carcinoma..Dig Dis Sci2019;64:269-80

[28] Lee HW,Lee SG.Patient selection by tumor markers in liver transplantation for advanced hepatocellular carcinoma..Liver Transpl2018;24:1243-51

[29] Lin CC.Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes..HepatoBiliary Surg Nutr2016;5:415-21 PMCID:PMC5075822

[30] Lin C,Chen C.Abdeldayem HM.Living donor liver transplantation for hepatocellular carcinoma..InTech;2017;

[31] Minagawa M.Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus..World J Gastroenterol2006;12:7561-7 PMCID:PMC4088035

[32] Lee YH,Huang YH.Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact..J Clin Gastroenterol2014;48:734-41

[33] Chen ZH,Lu YG.Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study..Hepatol Int;2020;

[34] Cheng S,Shen F.Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement..Oncotarget2016;7:40816-29 PMCID:PMC5130047

[35] Cerrito L,Iezzi R.Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers..World J Gastroenterol2019;25:4360-82 PMCID:PMC6710186

[36] Choi HJ,Na GH.The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation..Liver Transpl2017;23:1023-31

[37] Shi J,Li N.A new classification for hepatocellular carcinoma with portal vein tumor thrombus..J Hepatobiliary Pancreat Sci2011;18:74-80

[38] Peng SY,Huang CY.Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus..World J Gastroenterol2018;24:4527-35 PMCID:PMC6209573

[39] Huo L,Yan Z.Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus..Cell Biosci2019;9:23 PMCID:PMC6404349

[40] Cheng S,Cai J.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition..Oncotarget2017;8:8867-76 PMCID:PMC5352449

[41] Moriguchi M,Itoh Y.A review of non-operative treatments for hepatocellular carcinoma with advanced portal vein tumor thrombus..J Clin Transl Hepatol2017;5:177-83 PMCID:PMC5472939

[42] Soin AS,Kataria T.Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging..Transplantation2020;doi: 10.1097/TP.0000000000003162

[43] Lee KW,Choi YR.Macrovascular invasion is not an absolute contraindication for living donor liver transplantation..Liver Transplant2017;23:19-27

[44] Toso C,Kneteman NM.The place of downstaging for hepatocellular carcinoma..J Hepatol2010;52:930-6

[45] Akateh C,Conteh L.Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma..World J Gastroenterol2019;25:3704-21 PMCID:PMC6676544

[46] Aravinthan AD,Doyle AC.Liver transplantation is a preferable alternative to palliative therapy for selected patients with advanced hepatocellular carcinoma..Ann Surg Oncol2017;24:1843-51

[47] Jeong Y,Yoon SM.Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular carcinoma with vascular invasion..J Gastrointest Surg2017;21:275-83

[48] Yoon YI.Living donor liver transplantation for hepatocellular carcinoma: an asian perspective..Dig Dis Sci2019;64:993-1000

[49] Todo S.Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan..Ann Surg2004;240:451-9 PMCID:PMC1356435

[50] Zhu XD,Sun HC.Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects..Genes Dis2020;7:359-69 PMCID:PMC7452398

[51] Toso C,Bigam DL.De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects..Transplantation2007;83:1162-8

[52] Cholongitas E,Rodríguez-Castro KI.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review..Transpl Int2014;27:1039-49

[53] Geissler EK,Zölke C.Sirolimus use in liver transplant recipients with Hepatocellular carcinoma: a randomized, Multicenter, open-label phase 3 Trial..Transplantation2016;100:116-25 PMCID:PMC4683033

[54] Filgueira NA.Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation..World J Hepatol2019;11:261-72 PMCID:PMC6447422

[55] Huang L,Zhu JY.Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study..Onco Targets Ther2012;5:457-62 PMCID:PMC3532036

[56] Satapathy SK,Kocak M.No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant..Clin Transplant2018;32:e13246

[57] Noda S,Osaki R.Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study..Cancer Chemother. Pharmacol2020;86:129-39

[58] Lee MS,Hsu CH.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study..Lancet Oncol2020;21:808-20

[59] Kim R,Wang E.A phase i trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer..Oncologist2020;doi: 10.1634/theoncologist.2020-0759

[60] Berenguer M,Ghobrial M.Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference..Transplantation2020;1143-9

[61] Halazun KJ,Abdelmessih RM.Recurrence after liver transplantation for hepatocellular carcinoma..Ann Surg2017;265:557-64

[62] Lee JH,Kim HY.Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the milan criteria..Ann Surg2016;263:842-50

[63] Mazzaferro V,Zhou J.Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma..Gastroenterology2018;154:128-39